German pharmacies face financial crisis as high-cost drugs dominate revenue
Pharmacies across Germany are struggling with growing financial pressure as high-cost drugs now make up a large share of their revenue. While these medications represent less than half a percent of all prescriptions, their sales have more than tripled since 2010. The rising expenses, combined with delayed reimbursements, are forcing many pharmacies to seek early payouts to stay afloat.
The financial strain on German pharmacies has worsened over the past decade. High-priced medications, though rare in volume, now account for 40 percent of the sector's total revenue. This shift has left many pharmacies facing liquidity issues, especially when health insurers delay payments.
To ease cash flow problems, some pharmacies are turning to advance financing through clearinghouses. These services provide early payouts on prescription reimbursements, allowing pharmacies to cover upfront costs for expensive drugs. However, critics warn that over-reliance on such schemes could push some businesses toward insolvency.
Legal rulings, including a recent decision by the Federal Court of Justice (BGH IX ZR 182/23), have highlighted the risks of claim assignments and liquidity pressures. Clearinghouses charge fees for accelerated payments, adding another financial burden. Despite the risks, more pharmacy owners are using these services as high-cost drugs continue to dominate the market.
The growing share of expensive medications and delayed insurance payments are forcing pharmacies to rely on early financing options. While these advances help manage short-term cash flow, they come with fees and potential long-term risks. Without changes, the financial pressure on pharmacies is likely to persist.
